title: [Radiotherapy with androgen deprivation in high-risk prostate cancer: what outcomes on a Caribbean population?].
abstract: OBJECTIVE
  To analyze in a Caribbean population at 90% of African descent, the results of radiotherapy with androgen deprivation (AD) in high-risk prostate cancer (PCa).
  
  
  METHODS
  Fifty-nine consecutive patients with a high-risk PCa as defined by the D'AMICO classification and treated by radiotherapy with AD between January 2003 and April 2009 in our center were analyzed. The median dose of radiation and the median duration of AD were 70Gy and 37months respectively. Biochemical recurrence (BF), as primary outcome was defined according to the PHOENIX criteria (nadir PSA+2ng/mL). Multivariate analysis was performed to identify predictive factors of BF. The median follow-up was 47months.
  
  
  RESULTS
  Eight (13.6%) patients had BF and four (6.8%) developed metastases. Six (10.2%) died during the follow-up. The 5years acturial biochemical disease-free survival was 79.7%. Multivariate analyses have shown that Gleason sum (GS) superior to 7 (P=0.029), AD duration less than 24months (P=0.004) and the rate of Nadir PSA greater or equal to 0.5ng/mL (P=0.011) were independent predictive factors of BF.
  
  
  CONCLUSIONS
  This study was the first to our knowledge, to provide that radiotherapy associate with AD for HRPC among Caribbean men is effective as observed in other populations. Patients with GS superior to 7 could be considered for more aggressive treatments in clinical trials.
authors.affiliation: Service d'urologie andrologie, CHU Caremeau, Nîmes cedex, France. maxkadoch@hotmail.fr
authors.forename: A D
authors.initials: AD
authors.lastname: Foahom Kamwa
authors.forename: E
authors.initials: E
authors.lastname: Vian
authors.forename: G
authors.initials: G
authors.lastname: Agoua
authors.forename: C
authors.initials: C
authors.lastname: Sénéchal
authors.forename: Y
authors.initials: Y
authors.lastname: Bentaleb
authors.forename: M
authors.initials: M
authors.lastname: Fofana
authors.forename: N
authors.initials: N
authors.lastname: Manip-M'ebobisse
authors.forename: P
authors.initials: P
authors.lastname: Blanchet
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017691:Caribbean Region; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D012189:Retrospective Studies
chemical_list: D000726:Androgen Antagonists